Growing prevalence of patients suffering from various neurological disorders is the major factor driving the market growth of TD treatment. For example, In 2017 April, Neurocrine Biosciences has published a report which stated that about 5lakhs people are suffering from TD in U.S. Tardive dyskinesia treatment market is anticipated to grow significantly during the forecast period owing to rise in geriatric population, busy and tense lifestyle, growing prescription of anti-psychotic drugs etc. The factors which are hampering the growth TD market is approval process of new treatment approaches by respective governments, delayed diagnosis of the disease and lack of awareness regarding the disease.
A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Based on drug class, the tardive dyskinesia treatment market is segmented into the following
• Beta blockers
• Vitamin E systemic
• VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
• Dopaminergic agents
• Benzodiazepines
Based on route of administration, the tardive dyskinesia treatment market is segmented into the following
• Oral
• Parenteral
Based on distribution channel, the tardive dyskinesia treatment market is segmented into the following
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-c654SbFYO64MsOhu[/URL]
A variety of medicines are used to treat tardive dyskinesia such as clonidine etc. Botox injections can be given for minor TD. Vitamin B6, vitamin E and branched chain amino acids are helpful in minimizing the symptoms of tardive dyskinesia. Benzodiazepines therapy is the most effective therapy for tardive dyskinesia. However, the development of tolerance is restraining its growth in the market. Teva’s AUSTEDO was approved for the treatment of chorea associated with tardive dyskinesia. Austedo is likely to create competition for INGREZZA of Neurocrine Biosciences.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in global tardive dyskinesia treatment market are Biogen (U.S), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc.(U.K), Johnson & Johnson Services, Inc.(U.S), Pfizer Inc.(U.S), Neurocrine Biosciences, Inc.(U.S), Novartis AG(Switzerland), AstraZeneca (U.K), Bayer AG (Germany) and Sanofi (France).
Get access to full summary @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/[/URL]
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553